Esreboxetine

DB12395InvestigationalSmall molecule

Esreboxetine has been used in trials studying the treatment and basic science of Fibromyalgia.

Mechanism: Pharmacologically active on Sodium-dependent noradrenaline transporter
Curator reviewed
Formula / weight: C₁₉H₂₃NO₃ · 313.3908 g/mol (avg)

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyCBQGYUDMJHNJBX-OALUTQOASA-NSMILES[H][C@]1(CNCCO1)[C@@H](OC1=CC=CC=C1OCC)C1=CC=CC=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

680Drug interactionsStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Esreboxetine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.